Every day, oncology researchers are bringing us more insight into cancer. Every year, they share their exciting work at the annual American Society of Clinical Oncology (ASCO) conference. In this new white paper, Quintiles’ oncology experts Harish Dave and Eric Groves summarize the new findings and promising results presented at the June 2010 meeting.

With a keen understanding of today’s oncology challenges, they outline significant progress made in treatments for specific cancers including prostate, lung, melanoma, ovarian, colorectal and lymphoma. These remarkable advances are revolutionizing the standard of care and leading to more personalized approaches to treating cancer patients. Anyone involved in the clinical development of oncology therapies will want to check out this overview of innovations in treatment approaches.


About the Authors:  

Harish Dave, MD,Vice President, Medical and Scientific ServicesAs Vice President and Global Therapeutic Head of Hematology-Oncology and Transplantation, Dr. Dave offers drug development strategy and guidance and oversees hematology and oncology studies in all phases. He has 15 years of academic hematology-oncology experience, serving as a Principal Investigator on multiple studies. He has also chaired an NIH Study Section and the research and development committee at a major academic medical institution. In the latter capacity, Dr. Dave managed all research and Institutional Review Board-related activity, including more than 170 protocols annually. Board-certified in internal medicine, medical oncology and hematology, Dr. Dave was previously Associate Professor of Medicine at George Washington University and Assistant Chief of Hematology and Chief of Laboratory of Molecular Hematology at the Veterans Affairs Medical Center in Washington, D.C.

Eric Groves, MD, PhD, Executive Global Strategic Drug Development Director
Board-certified in oncology and internal medicine, Dr. Groves has more than 20 years of experience in drug development as a corporate officer, clinician and researcher. Prior to joining Quintiles in 2007, Dr. Groves was at Ligand Pharmaceuticals, where he served as Vice President, Project Manager and Corporate Officer. Dr. Groves has also held a number of positions at Sanofi Pharmaceuticals, most recently as Vice President, Project Direction, where he was responsible for worldwide strategy for the company’s oncology projects. From 1991 to 1994, Dr. Groves served as Senior Project Director for the research division of Sterling Winthrop Corporation, where he was also acting Vice President of Discovery and Clinical Research in the immunoconjugate division. He was Director of Clinical Research and Development at CETUS Corporation from 1989 to 1991.